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Methylphenidate enhances neuronal
differentiation and reduces proliferation
concomitant to activation of Wnt signal
transduction pathways
Edna Grünblatt 1,2,3, Jasmin Bartl1,4 and Susanne Walitza 1,2,3
Abstract
Methylphenidate (Ritalin) is the most commonly prescribed drug in the treatment of attention-deﬁcit hyperactivity
disorder. It is suggested that in vivo, methylphenidate treatment supports cortical maturation, however, the molecular
and cellular mechanisms are not well understood. This study aimed to explore the potential effect of methylphenidate
on cell proliferation and maturation in various cellular models, hypothesizing its interaction with the Wnt-signaling.
The termination of cell proliferation concomitant to neuronal maturation following methylphenidate treatment was
observed in all of the cell-models tested: murine neural stem-, rat PC12- and the human SH-SY5Y-cells. Inhibition of
Wnt-signaling in SH-SY5Y cells with Dkk1 30 min before methylphenidate treatment suppressed neuronal
differentiation but enhanced proliferation. The possible involvement of the dopamine-transporter in cell differentiation
was discounted following the observation of opposing results after GBR-12909 treatment. Moreover, Wnt-activation via
methylphenidate was conﬁrmed in Wnt-luciferase-reporter assay. These ﬁndings reveal a new mechanism of action of
methylphenidate that might explain long-term effects.
Introduction
The neurodevelopmental disorder attention-deﬁcit
hyperactivity disorder (ADHD) is one of the most com-
mon psychiatric and behavioral disorders in children and
adolescents, often persisting into adulthood1. Delayed cer-
ebral cortex maturation (thickness and surface area), in
particular in frontal regions known to be important in the
control of cognitive processes concomitant to alterations in
basal ganglia formations, were reported in children and
adolescents with ADHD2,3. These have also been linked to
adult ADHD4. Moreover, ventral and dorsal striatal surface
reduction, associated with reward processing, executive
function and motor planning, respectively5,6 have also been
observed in ADHD. Psychostimulants, in particular
methylphenidate (MPH) and amphetamine, provide an
effective treatment for ADHD7, although their effects on
brain development, maturation and its safety have been
discussed controversially8–11. Nevertheless, several studies
point to the beneﬁcial effects of psychostimulant treatment
on brain function and structure in ADHD6,9–11. So far it is
known that MPH binds with high afﬁnity to the dopamine
transporter, and with lower afﬁnity to the norepinephrine
transporter and serotonin transporter, and inhibits the
transport of synaptic monoamines back into the neuron12.
However, given the extent of MPH prescription13, and the
levels of misuse amongst youth and young adults14, parti-
cularly at sensitive developmental stages in regard to brain
maturation, concerns over adverse effects (e.g., neurogen-
esis, neuronal development, maturation, receptor densities
or connectivity) have been raised. Few studies have looked
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into neurodevelopmental effects of MPH treatment, in vitro
and in vivo. In vivo, several studies have observed that MPH
treatment was associated with neurogenesis and cell dif-
ferentiation in rodents15,16. Recently, 2 and 5mg/kg (oral)
MPH treatment in adolescent rats over a ﬁve-week period
reportedly increased hippocampal neurogenesis and inward
shape deformations. This was not observed in adult rats
with the same treatment17. An in vitro study of neuronal
maturation following MPH treatment (1–100 nM, doses
correlating to oral intake of 1mg/kg MPH in patients’
serum18,19) in murine neural stem cells (mNSC) found that
MPH enhanced cell differentiation, but inhibited cell pro-
liferation20. However, the cellular and molecular mechan-
ism affected by MPH treatment is not yet fully understood.
Therefore, the current study aims to extend our pre-
vious mNSC pilot study20 by using three cell culture
models: mNSC, rat pheochromocytoma-12 (PC12) and
the human neuroblastoma SH-SY5Y cells. Moreover,
following the observed differentiation effect of MPH on
the cells, we hypothesized the possible involvement of the
canonical Wnt-signaling pathway21–23. Our hypothesis is
based on the fact that Wnt-signaling plays a role in several
cellular and physiological processes, regulating cell pro-
liferation, differentiation, migration, and patterning dur-
ing embryonic development, and tissue homeostasis in
adults, but is speciﬁcally needed in the maturation and
differentiation of NSC24. Two approaches will be used to
test this hypothesis. First, a pharmacological approach in
Fig. 1 Effect of MPH on embryonic mNSC differentiation into astrocyte (GFAP+ cells) and neurons (Tuj1+ cells). a Representative
immunocytochemistry staining (control, MPH 10 nM and 10 μM; see Supplementary Fig. S1 for all MPH doses) of embryonic mNSC against GFAP
(red), Tuj 1 (green) and for total cell count using Hoechst 33258 staining (blue). Scale bar= 50 µm. b MPH treatment induced differentiation of mNSC
into Tuj1 positive neurons showing signiﬁcance starting with 10 nM MPH treatment, while suppressing differentiation into GFAP-positive astrocytes.
Results presented as percent of control treatment showing mean value, and the s.e.m. Kruskal–Wallis followed by Mann–Whitney Test *p < 0.05 vs.
control, **p < 0.01 vs. control, ***p < 0.001 vs. control; n= 5 repeats
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which we will compare the effects of treating the human
SH-SY5Y cells with MPH to those treated with either R-
spondin 1 (Wnt activator), GBR-12909 (selective dopa-
mine transporter inhibitor), or by blocking the Wnt-
signaling with Dickkopf-1 (Dkk1; antagonistic inhibitor of
the Wnt-signaling, binds to low-density lipoprotein
receptor-related protein 5/6; LRP5/6) 30 min before MPH
treatment. In the second approach, we will use a cell-
based luciferase assay in mouse ﬁbroblast cells engineered
with the ﬁreﬂy luciferase reported gene under the control
of Wnt-responsive promoters (TCF/LEF), enabling us to
measure Wnt/β-catenin-activity after pharmacological
treatment with MPH.
Material and methods
Preparation of compound solution
Speciﬁcation of compound solution preparation is
described under Supplementary Material And Methods in
details.
Murine neuronal stem cell (mNSC) sphere monolayer
culturing and differentiation study
mNSCs were derived from the hippocampus tissue of
albino mouse (Charles River, Switzerland) embryos on
embryonic day 15 (E15). All animal procedures were
performed in accordance with National Institute of
Health, and the Cantonal Veterinary ofﬁce Zurich for the
care and use of laboratory animals’ guidelines (Ethic
permission 223/2014). Cells were cultured in a deﬁned
medium (NeuroCult Proliferation Kit (Mouse); Stemcell,
Germany) for 6 days at 37 °C and 5% CO2. After 6 days,
the grown NSC spheres were harvested and prepared for
differentiation. mNSC spheres were collected and plated
on a 30 μg/ml poly-L-lysine (Sigma aldrich, Switzerland)
and 20 μg/ml laminine (Invitrogen, Switzerland) coated 8-
well glass cover-slip and incubated for another four days
creating a monolayer (see example Fig. 1a). Each well had
a ﬁnal concentration of 22.8 × 104 cells/ml cultured in
NeuroCult Differentiation Kit (Mouse) (Stemcell, Ger-
many). The cells were treated directly after seeding to the
cover-slip using different concentration (1 nM, up to 100
μM) of MPH or water as control. On the last day, cells
were ﬁxed with 4% paraformaldehyde for 20min at room
temperature and stained for glial ﬁbrillary acidic protein
(GFAP; 1:200, Sigma aldrich, USA, Cat-No: C4546), β-
tubulin III (Tuj 1; 1:300, Sigma aldrich, USA, Cat-No:
T3952), and Hoechst 33258 staining (1:100; Invitrogen,
Cat-No: H3569) (for detailed Immunocytochemistry
procedure see supplementary material and methods).
Statistical analysis
The staining’s were analyzed for the cell count of
astrocytes (GFAP-positive cells) and immature neurons
(Tuj 1 positive cells) in comparison to the total number of
cells (Hoechst positive cells) using the Kruskal–Wallis
followed by Mann–Whitney Test. In order to present
results in comparison to the untreated cells, percentages
were calculated for each treatment dose, setting the
control as 100%. Analysis was conducted using SPSS
version 22 software program (IBM, USA). A p-value <
0.05 was set as signiﬁcant. There were at least ﬁve inde-
pendent experiments, and ﬁve pictures per well (treat-
ment) were analyzed.
Neuronal cell line culture
For the standard culturing and differentiation procedure
of human neuroblastoma SH-SY5Y cells (European Col-
lection of Authenticated Cell Cultures (ECACC), UK) and
rat pheochromocytoma (PC12) cells (ECACC, UK) see
supplementary material and methods.
Treatment of SH-SY5Y and PC12 cells
In the proliferating experiment, PC12 cells were treated
once with either MPH or water (Fig. 2a). In the differ-
entiation experiment, PC12 cells were treated every 24 h
with either MPH or water and the morphological classi-
ﬁcation of cell differentiation was done after 6 days of
culturing in differentiation medium (DM), consisting of a
normal growth medium supplemented with 10 μM reti-
noic acid (Sigma Aldrich, Switzerland) and 50 ng/ml
nerve growth factor (Sigma Aldrich, Switzerland; Fig. 2d).
In the proliferating experiments, SH-SY5Y cells were
treated once with either MPH, GBR12909 (cat. no. D052;
Sigma Aldrich, Switzerland), R-spondin 1 (cat. no.
SRP6487; Sigma Aldrich, Switzerland), compared to
vehicle water or DMSO. For Wnt-signaling pathway
inhibition, Dkk-1 (cat. no. SRP3258; Sigma Aldrich,
Switzerland) was added 30min before cells were treated
with MPH (Fig. 3a, b). In the differentiation experiment,
SH-SY5Y cells were treated every 24 h with different
doses of either MPH, GBR12909, R-spondin 1, compared
to vehicle water or DMSO. While in the Wnt-signaling
pathway inhibition, Dkk-1 was added 30 min before cells
were treated with MPH. The morphological classiﬁcation
of cell differentiation was conducted after 3 days of cul-
turing in DM (Fig. 4a, b).
xCELLigence analysis for cell proliferation or cytotoxicity
Cell viability and proliferation after acute treatment
with MPH was monitored using the real-time xCELLi-
gence analyzer from Roche. 96-well E-plates (ACEA,
USA) were coated using 40 µl/well collagen-I solution
(ScienCell, USA) for both cell types. The background cell
impedance of the pure growth medium without cells was
measured, before SH-SY5Y cells were seeded at a con-
centration of 5×104 cells/well and PC12 at 1×104cells/
well. The baseline cell index (CI) was measured every
15min for 24 h. Afterwards the cells were treated with
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different doses of MPH, whereas CI was measured con-
tinuously every minute for two hours and every 15min for
another 48 h.
Statistical analysis of xCELLigenece results Raw data
from the xCELLigence system presented as CI values were
used for the statistical analysis with the statistical software
program StatView 5.0 (SAS Institute Inc.Cary, NC, USA).
Determination of the ﬁrst signiﬁcant time point in which
MPH alters cell proliferation in comparison with
untreated cells was conducted using self-written
MATLAB programs in which all impedance measures
with time and dose were evaluated (Supplementary Fig. S2
B and C). For this, the CI data were exported from the
xCELLigence software into an excel ﬁle followed by coma
separated value ﬁle. For each time point measurement,
outliers were detected and removed (CI values more than
two s.d., but only if it was more than one s.d. away from
the plate mean at this time point). Comparison was
carried out for each measured time point by calculating
mean, s.d. and number of wells used to calculate the two
values for the two replicate groups. The Welch’s t-test was
applied. The p-value was plotted semi logarithmic and
with inverted axis against the time scale, thus the more
signiﬁcant a p-value, the higher the peak on the plot. p-
value < 0.01 were set as signiﬁcant (Supplementary Fig.
S2C). The demonstrated values were calculated in percent
relative to control levels (100%; control was water).
BrdU Incorporation
The SH-SY5Y cells were seeded into poly-D-lysine/
laminin coated eight-well slides at a density of 3×104 cells/
well and the PC12 cells were seeded at the same density
into Collagen I coated eight-well slides. The cells were
incubated at 37 °C in a humidiﬁed atmosphere of 5% CO2
for 24 h. SH-SY5Y cells were treated with different doses
of MPH (1 nM–100 µM), GBR12909 (1 nM–10 µM), R-
Spondin1 (100 ng/ml), dkk1 (200 ng/ml) alone, or 30 min
before MPH was added, (vehicle was water or DMSO) and
incubated for 16 h. This time point of assessment was
determined according to the xCELLigence results (see
section ‘xCELLigence analysis for cell proliferation or
cytotoxicity’). PC12 cells were treated with either MPH or
water followed by incubation for 16 h. After incubation
10 μM of the thymidine-analog 5-bromodeoxyuridine
PC12 Cell
Seeding
Time 
(Hours)
-24 86127840 96
MPH /
water
24 144
MPH /
water
MPH /
water
MPH /
water
MPH /
water
MPH /
water
Staining
Control
50µM
1nM MPH 10nM MPH
100nM MPH 10µM MPH
100µM MPH
D.
E.
F.
PC12 Cell
Seeding
Time 
(Hours) -24 270
MPH /
water
16
BrdU
xCELLigence measurements
A.
B. C.
1µM MPH
Fig. 2 Inﬂuence of MPH treatment on PC12 cells proliferation and
differentiation. Proliferation: (a) the time line of cell culturing,
treatment and proliferation measurements. b Mean cell index
(impedance measured by xCELLigence) values as % of control ± s.e.m.
at 16 h after MPH treatment (1 nM–100 µM) showing signiﬁcant
decrease in cell proliferation. c Mean of BrdU positive cells as % of
control ± s.e.m. at 16 h after MPH treatment (1 nM–100 µM) resulted in
a signiﬁcant decrease in cell proliferation. Mann–Whitney *p < 0.05;
**p < 0.01; ***p < 0.005. Differentiation: (d) the time line of cell
culturing, treatment and neurite outgrowth determination via ‘Neurite
outgrowth staining kit’ (Thermo Fisher) for differentiation evaluation. e
Representative neurite outgrowth staining of vehicle and MPH
(1 nM–100 µM) treated PC12 cells. Scale bar= 50 µM. f Neurite
outgrowth was signiﬁcantly increased after 10 nM up to 100 μM MPH
treatment. Mann–Whitney test **p < 0.05 and ***p < 0.01 vs. control. n
= 4–5 independent experiments with 4–6 internal replications
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Fig. 3 (See legend on next page.)
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(BrdU) was added to the cells and incubated for 4 h at 37 °
C. Cells were ﬁxed with 4% ice-cold paraformaldehyde
(SantaCruz Biotechnologies, Switzerland) followed by
standard procedure of staining (see Supplementary
Material And Methods). Pictures were taken at ×20
magniﬁcation under the inverted microscope (Olympus
IX81, Germany) with DP72 Digital camera. Cells were
counted using the xcellence software (Olympus,
Germany).
Cytotoxicity and apoptosis
ApoTox-Glo Triplex Assay and CellTox Green Cyto-
toxicity Assay from Promega (Switzerland) were used to
determine the possible toxic effect of MPH on PC12 cells.
For testing the cytotoxicity and apoptosis effect, PC12
cells were seeded at 104 cells/well onto Collagen I treated
black 96-well plates and were cultivated for 24 h at 37 °C
in 5% CO2. Afterwards cells were treated with different
concentration of MPH and reaction was measured 24 h
later. The assays were performed according to the man-
ufacturer´s protocol.
Measurement and quantiﬁcation of cell differentiation
To determine neurite outgrowth, which is a hallmark of
differentiated cells, of PC12 and SH-SY5Y cells the
Neurite Outgrowth Kit purchased from Thermo Fisher
Scientiﬁc (Switzerland) was used to stain the cell pro-
cesses. The manufacturers protocol was slightly altered by
substituting PBS with Opti-MEM (Thermo Fisher Scien-
tiﬁc, Switzerland), since a loss of cells and breaking of
longer neurites was observed when strictly adhering to the
protocol. After aspiring the medium, the cells were
stained with a working stain solution (3 μl of cell mem-
brane indicator and 3 μl cell viability indicator in 3 ml
Opti-MEM) for 15min. The stain solution was then
replaced by a background suppressor solution and pic-
tures were taken on the Olympus DP72 microscope, using
20 ×magniﬁcation. Per experiment, ﬁve representative
images per condition containing at least ﬁve neurons were
analyzed using the xcellence software (Olympus, Ger-
many). To determine the differentiation state the ratio of
neurite length to diameter of soma was taken as a refer-
ence. Astrocytes, glia cells and other cell types, which can
still appear in cell culture, were not considered for
analysis.
Statistical analysis
Statistical analysis was done using Prism (Graphpad
Software, version 6.0). The statistical analysis of xCELLi-
gence was done via StatView and MATLAB. Results are
given as mean ± s.e.m. Analysis was conducted using
Mann–Whitney test with p < 0.05 set as signiﬁcant. For
proliferation analysis over 18,000 cells were calculated
and for differentiation study over 2100 cells. All experi-
ments were repeated at least three times independently.
Activity detection of canonical Wnt-signaling with
luciferase Wnt reporter assay
To conﬁrm our pharmacological analysis of the Wnt-
signaling activation by MPH and R-Spondin1 against
Wnt-signaling inhibition via Dkk1, we used the Leading
Light Wnt Reporter Assay (Enzo Life Sciences, Lausen,
Switzerland). The cell-based luciferase activity assay was
conducted with some modiﬁcations to the manufacturer
protocol (Supplementary Material And Methods). Fol-
lowing, Wnt agonist activity was run by adding to the cells
either 5 µl R-Spondin1 100–1000 ng/ml (Sigma, Switzer-
land), Wnt3a 5–200 ng/ml (abcam, Switzerland), LiCl
5–40mM (Sigma, Switzerland), or MPH 1 nM up to
1mM (all diluted in H2O). Water was used as a negative
control. Wnt antagonist activity test was conducted by
adding to the cells already treated with Wnt3a 100 ng/ml
the potential antagonist Dkk-1 20-200 ng/ml (5 µl; Enzo
Life Science, Switzerland), or 5 µl MPH 1 nM up to
100mM. Cells were incubated at least 12 h, washed with
PBS, followed by 15min incubation with lysis buffer
(Biotium, USA). Lysates were transferred into white
microplate (Berthold, Germany) and mixed with luciferin
assay buffer (Biotium, USA). Chemiluminescence reaction
was measured immediately using the Mithras LB943
(Berthold, Germany) resulting in relative luciferase unite
(RLU) measures. All experiments were conducted with
(see ﬁgure on previous page)
Fig. 3 Inﬂuence of MPH treatment on SH-SY5Y cells proliferation and the involvement of Wnt-signaling. a The time line of cell culturing,
treatment with either MPH (1 nM–100 μM), GBR12909 (selective dopamine transporter inhibitor; 1 nM–100 μM) or R-spondin 1 (R-spo1; Wnt activator,
100 ng/ml) and proliferation measurements. b The time line of cell culturing, inhibiting Wnt-signaling by treating cells with Dkk1 (LRP inhibitor;
200 ng/ml) half an hour before MPH treatment and proliferation measurements. c Mean cell index (impedance measured by xCELLigence) values as
% of control ± s.e.m. at 16 h after MPH treatment (1 nM–100 µM) showing signiﬁcant decrease in cell proliferation. d Mean of BrdU positive cells as
percentage of control ± s.e.m. at 16 h after MPH treatment (1 nM–100 µM) resulted in lower cell proliferation. Blocking Wnt-signaling using Dkk1
enhanced signiﬁcantly cell proliferation. Similarly, inhibiting Wnt-signaling with Dkk1 30 min before MPH treatment resulted in increased proliferation.
As expected, activation of Wnt-signaling by R-spondin 1 reduced proliferation of the cells. Moreover, the selective dopamine transporter inhibitor
GBR12909 did not affect SH-SY5Y cell proliferation. n= 5 independent experiments; N= 18302 counted cells; Mann–Whitney test, *p < 0.05, **p <
0.01, ***p < 0.001
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internal and external replications of 4–38. Regression was
conducted using the exponential regression equation.
Sclerostin-LRP interaction assay
LRP might also be involved in MPH activation of Wnt-
pathway, since activation of Wnt occurs via binding of
Wnt-ligands to Frizzled (Fz) and LRP receptor, triggering
the canonical Wnt-signaling cascade25. In the regulation
of bone formation, sclerostin, encoded by the SOST gene,
can bind to LRP5/6, causing inhibition of the canonical
Wnt signaling26. To evaluate, whether MPH interacts
with the sclerostin-LRP binding, the Leading Light
Sclerostin Interaction Screening (Enzo Life Sciences,
Lausen, Switzerland) in a 96-well system was used, fol-
lowing manufacturer manual (Z′-factorreproducibility=
0.871). Fifty microliter MPH starting from 1 nM up to
1mM all diluted in Assay Buffer (Enzo Life Sciences,
Lausen, Switzerland) containing LRP-AP fusion protein,
were added to the sclerostin pre-coated plate. As positive
control for binding activation, only Assay buffer con-
taining LRP-AP fusion protein was added. Each con-
centration was tested in 6-plicates. As negative control the
sclerostin binding inhibitor Acid Green (Enzo Life Sci-
ences, Lausen, Switzerland) and as background control
Assay Buffer without LRP-AP was used. After incubation
of two hours, wells were washed 4× followed by the
addition of 50 µl AP substrate reagent (Enzo) per well.
After 25 min of incubation, chemiluminescence reaction
was measured using the Mithras LB943 (Berthold, Ger-
many) resulting in RLU measures. Statistical analysis was
done using StatView (v. 5.0, SAS Institute Inc.). Results
are given as mean RLU ± s.e.m. Analysis was conducted
using Kruskal–Wallis followed by Mann–Whitney test
with p < 0.05 set as signiﬁcant.
Gene expression omnibus (GEO) search for data sets of
MPH treatment inﬂuence on transcriptomic proﬁling and
enrichment analysis
A search of data sets under GEO was conducted for
gene expression proﬁling results after MPH treatment
conducted in mammals with the keyword ‘methylpheni-
date’ and limiting the search to the ‘expression proﬁling
by array’ study type. Three data sets could be found
(excluding one dealing with autism spectrum disorder)
using these terms: (1) MPH effect on mouse substantia
nigra27—GSE33619, (2) Psychostimulant (MPH, amphe-
tamine and methamphetamine) effects on rat striatum
and prefrontal cortex28—GSE33619, and (3) MPH effects
on human lymphoblastoids29—GSE52889. Following this,
each of the data sets were uploaded onto the Pathway
Studio software (Elsevier; v. 11.4.08) to run the gene
expression proﬁling and statistics correcting for multiple
testing with Benjamin–Hochberg (FDR). The signiﬁcant
(p < 0.05) mRNA proﬁles found to alter as a consequence
of MPH treatment were investigated for their enrichment
in pathways and functional groups using the Gene-Set
Enrichment Analysis (GSEA) tool of the Pathway Studio
software (Elsevier; Mammal database), which calculates
statistical signiﬁcance of concordant differential expres-
sion for set of genes in pathways, groups, and predeﬁned
gene sets between two biological states using ratio (log-
ratio) values of genes. Signiﬁcant results (p < 0.0005) for
enrichment analysis are presented in Supplementary
Material S1. Gene Ontology (GO), pathways, diseases and
signal processing related to brain or neuronal processes
were marked in green, while Wnt-pathway was marked in
blue (Supplementary Table S1).
Data availability
The data that support the ﬁndings of this study are
available from the corresponding author upon request.
Results
MPH effects on embryonic mNSC differentiation
In order to expand on our previous pilot study20, we
examined the acute effect of a range of MPH doses up to
100 μM on embryonic mNSC differentiation. MPH
treatment at 1 nM and up to 100 nM enhanced cell dif-
ferentiation into immature neurons detected by positive
staining for neuron-speciﬁc class III β-tubulin (Tuj1) (Fig.
1; Supplementary Fig. S1), similar to our previous pilot
study20. We expanded further on this ﬁnding and
demonstrated that increasing MPH doses up to 100 μM
further increased immature neurons density to 207 ± 39%
(see ﬁgure on previous page)
Fig. 4 Inﬂuence of MPH treatment on SH-SY5Y cells differentiation and the involvement of Wnt-signaling. a The time line of cell culturing,
treatment with either MPH (1 nM–100 μM), GBR12909 (selective dopamine transporter inhibitor; 1 nM–100 μM) or R-spondin 1 (R-spo1; Wnt activator,
100 ng/ml) and neurite outgrowth determination via ‘Neurite outgrowth staining kit’ (Thermo Fisher) for differentiation evaluation. b The time line of
cell culturing, inhibiting Wnt-signaling by treating cells with Dkk1 (LRP inhibitor; 200 ng/ml) half an hour before MPH treatment and differentiation
evaluation. c Representative neurite outgrowth staining of vehicle, MPH (100 µM), GBR12909 (10 µM), Dkk1 (200 ng/ml), Dkk1+MPH (100 µM) and R-
spondin 1 (100 ng/ml) treated SH-SY5Y cells. Scale bar= 50–100 µM. d Neurite outgrowth was signiﬁcantly increased after MPH treatment, which was
inhibited signiﬁcantly by Dkk1 treatment. Similar to MPH, R-spondin 1 treatment increased signiﬁcantly cell differentiation. However, the selective
dopamine transporter inhibitor, GBR12909, caused a signiﬁcant decrease in SH-SY5Y cell differentiation, while the higher dose of 100 µM induced cell
death. n= 3–5 independent experiment; N= 2172 measured cells; Mann–Whitney test, **p < 0.05, ***p < 0.001 vs. control
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of control (Mann–Whitney test U=−2.021, Asymp. p=
0.043, Exact p= 0.057; Fig. 1). Additionally, mNSC trea-
ted with MPH in all doses did not result in a signiﬁcantly
different number of cells differentiating into astrocytes
(Glial ﬁbrillary acidic protein/ GFAP-positive staining)
compared to control (Fig. 1). On the contrary, a tendency
toward an inhibitory effect was observed when treating
the cells with the lower dose of 1–100 nM MPH.
Inﬂuence of MPH on rat PC12 cells proliferation and
differentiation
Following the possible inﬂuence of MPH on cell
development, as found in the mNSC, we tested the effects
of MPH on the proliferation of PC12 cells (Fig. 2). In
order to evaluate cell proliferation in a non-invasive and
non-biased manner, the real-time cell impedance auto-
matic monitoring (xCELLigence system) was used for a
duration of 72 h to evaluate the ﬁrst signiﬁcant time-point
at which MPH caused alterations (Fig. 2b and Supple-
mentary Fig. S2). Accordingly, 1–100 nM MPH sig-
niﬁcantly inhibited PC12 cell proliferation starting 16 h
after treatment, which was further conﬁrmed by assessing
the 5-bromodeoxyuridine (BrdU) positive cells (Fig. 2c).
In order to ensure that the effect did not arise from cell
death, apoptosis and cytotoxicity were measured, and
demonstrated negligible signals after MPH treatment
(Supplementary Fig. S2d–e), suggesting that there was no
signiﬁcant cell death due to MPH.
Daily treatment (5 days) of MPH starting from a 10 nM
up to a 100 μM dosage, signiﬁcantly promoted PC12 cell
differentiation, as observed by measuring neurite length
normalized to the diameter of the soma (Fig. 2d-f).
Inﬂuence of MPH on human SH-SY5Y cells proliferation
and differentiation
After testing proliferation and differentiation alterations
following MPH treatment in two non-human cellular
models (mouse and rat), we conﬁrmed a decrease in the
proliferation of SH-SY5Y cells after MPH treatment, as
measured both by the real-time impedance cell analyzer
and BrdU staining, starting with the lower 1 nM MPH
dose (Fig. 3a, c, d). Furthermore, we conﬁrmed that MPH
signiﬁcantly promoted the differentiation of SH-SY5Y
cells (Fig. 4). To exclude the possibility that the effects of
MPH on proliferation and differentiation were due to the
dopamine transporter inhibition, SH-SY5Y cells were
treated with the selective dopamine-transporter inhibitor
GBR12909. GBR12909 (1 nM up to 10 µM) treatment did
not cause a decrease in proliferation as with MPH (Fig.
3d), but rather a slight non-signiﬁcant increase was
observed. GBR12909 (1 nM up to 10 µM) treatment led to
a signiﬁcant decrease in differentiation (Fig. 4d), which
was in contrast to MPH treatment effects. Furthermore,
higher doses of GBR12909 (doses of 100 µM) caused cell
death in both the proliferation and differentiation
experiments, suggesting that increased extracellular
dopamine might have caused cytotoxicity.
Activation of Wnt/β-catenin pathway through MPH
treatment
Examining whether the observed effects on proliferation
and differentiation after MPH treatment were through the
activation of the Wnt/β-catenin pathway was investigated
by blocking the Wnt-pathway with Dkk1 30min before
MPH treatment. Indeed, Dkk1 treatment caused a sig-
niﬁcant increase in the proliferation of SH-SY5Y cells
(Fig. 3d), which remained constant after MPH treatment
(30 min after blocking the pathway). Controlling for Wnt-
activation effects using R-spondin 1 treatment resulted in
decreased proliferation as observed with MPH alone (Fig.
3d). Differentiation of SH-SY5Y cells was signiﬁcantly
inhibited by Dkk1 treatment 30min before MPH treat-
ment (Fig. 4d), whilst the activation of the Wnt-pathway
with R-spondin 1 signiﬁcantly increased differentiation
similar to MPH treatment alone (Fig. 4d).
In order to verify the activation of Wnt-pathway
through MPH treatment, the luciferase Wnt reporter
assay was used, showing a dose response activation of the
Wnt-pathway through Wnt3a, R-spondin 1 and LiCl
(Supplementary Fig. S3a–c), while Dkk1 treatment led to
an inhibition of the Wnt-pathway after Wnt3a treatment
(Supplementary Fig. S3d). Similarly, MPH from 1 nM up
to 100 µM resulted in an exponential increase in Wnt-
signaling activation (Fig. 5a). MPH treatment accom-
panied by 100 ng/ml Wnt3a protein enhanced the already
occurring activation (Fig. 5b), in contrast to the inhibitory
effect observed for Dkk1 when accompanied with 100 ng/
ml Wnt3a (Supplementary Fig. S3d).
LRP, in particularly 5 and 6, is known to activate the
canonical Wnt-signaling via binding with the Frizzle (Fz)
and Wnt protein25. Several mechanisms are existing for
regulating Wnt-signaling activation as the inhibitor Dkk1.
Furthermore, sclerostin inhibits activation of Wnt-
signaling via binding to LRP5/6, which also regulates
bone formation26. MPH inhibited LRP5 binding to scler-
ostin (ca, 17%) measured using the Leading Light
Sclerostin-LRP interaction screening kit (Enzo Life Sci-
ences Inc. Lausen, Switzerland) in all doses tested (1 nM
up to 1mM) with the strongest inhibition at 1 mM MPH
(Supplementary Fig. S4).
Enrichment analysis for GEO proﬁles following MPH
treatment
We re-analyzed three available gene expression proﬁle
data sets extracted from the GEO database, from experi-
ments studying MPH treatment effects in mouse sub-
stantia nigra27, in rat striatum and frontal cortex28, and in
immortalized human lymphocytes of controls and adult
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ADHD patients29, in which in the last study cell lines were
acutely treated with ca. 111 μM MPH. Pathway enrich-
ment analysis for all signiﬁcantly altered transcripts was
carried out using the GSEA. Indeed, we found some
indication that in vivo MPH treatment in mice and rats
induced mRNA alterations enriched in pathways involved
in cell differentiation and Wnt-signaling, as well as in
synaptic, axonal and neuronal processes (Supplementary
material S1). The top ranked pathways were of general
processes, such as plasma membrane, atlas signaling, cell
differentiation, signal transduction etc. followed by the
aforementioned pathways with p-values lower than
Fig. 5 Effect of MPH on the luciferase Wnt reporter assay activation/inhibition. a Dose response of MPH on the activation of the leading light
Wnt reporter assay represented as response ration (ratio= 1 negative control-water); b Dose response of MPH in the presence of Wnt3a (100 ng/ml)
on the activation/inhibition of the Leading Light Wnt reporter assay represented as response ration (ratio= 1 negative control-water); n= 17–35;
Exponential regression was conducted ﬁtting the curve with R2 > 0.9
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0.0005. In the human lymphoblastoids, enrichment in
synaptic, axonal and neuronal processes was observed
when comparing between adult ADHD and control cells
treated with saline, and in negative regulation of cell
proliferation and axonal guidance in cells treated with ca.
111 μM MPH (Supplementary material S1).
Discussion
This study found that MPH inﬂuences proliferation and
differentiation processes through Wnt-signaling activa-
tion. Evidence for Wnt-signaling activation through MPH
treatment was demonstrated using the cell culture model,
the luciferase Wnt-reporter assay as well as from GSEA
results of three gene expression databases in animals and
humans following MPH treatment. In all the above
experiments, we repeatedly conﬁrmed that MPH treat-
ment led to an alteration in Wnt-signaling pathways,
which at the cellular level promoted cell differentiation
concomitantly to reduced proliferation.
Modulation of Wnt-signaling components is known to
be induced by cocaine, an addictive psychostimulant.
Cocaine has been shown to cause a widespread down-
regulation of Wnt-signaling molecules in the nucleus
accumbens of mice, a key brain region in reward30, as well
as a downregulation of the Wnt-canonical pathway after
induction of cocaine sensitization in the prefrontal cortex
of rats, amygdala and dorsal striatum31. On the other
hand, amphetamine, (another ﬁrst–line treatment of
ADHD, e.g., according to the often used Canadian
guidelines (CADDRA) and second-line treatment
according to the most other guidelines), reportedly sti-
mulated Wnt3 with an increase in total β-catenin in rat
nucleus accumbens32. In adult mice with inducible
expression of Dkk1, there was a degeneration of cortico-
striatal synapses, but amphetamine did not increase
locomotion as compared to those treated with saline33.
However, induced Dkk1 adult mice were already slightly
hyperactive compared with control animals33, which
suggest that developmental timing of such induced
imbalance is important in Wnt activity. Although one
might hypothesize that psychostimulants effects on Wnt-
signaling may be due to monoamine levels or dopamine
receptor activity modulation, we did not observe such
changes after treatment with the selective dopamine-
transporter inhibitor GBR12909. Moreover, an increased
dose of GBR12909 led to cell death that was not observed
with MPH, even after higher doses. Although this suggests
that MPH has a direct interaction with Wnt-pathways,
this requires further investigation.
Alterations during neurogenesis and the plasticity of the
developing brain, as well as later in life, are often dis-
cussed to be vulnerability factors for the development of
psychiatric disorders, such as ADHD. Wnt-signaling has
been shown to regulate both embryonal neurogenesis, in
particular in the dopaminergic system22, as well as adult
neurogenesis processes mostly known to occur in the
hippocampus23. Various animal models and paradigms
have demonstrated MPHs capability to modulate neuro-
genesis and brain plasticity15–17,34. Recently, personalized
ﬁngerprinting of brain functional connectome demon-
strated sensitive time points in brain maturation and
plasticity, that were distinctively different to those with
symptoms such as attention deﬁcit35,36. Psychostimulant
treatment in ADHD was reported to induce changes in
functional brain connectivity, which were also associated
with symptom improvements37,38. Such alterations need
to be further understood in terms of the optimum time
point and duration of treatment with psychostimulants to
reach best results and beneﬁts.
There is some evidence for candidate risk genes in
ADHD to be enriched in pathways such as neurite out-
growth, axon guidance, cell trafﬁcking processes, brain
development, neurogenesis, and Wnt/β-catenin path-
way39–41. Wnt-signaling is known to play an important
role in the development and survival of neuronal cells in
the CNS. Moreover, growing evidence indicates that Wnt-
signaling pathways also regulate the structure and func-
tion of the adult nervous system. Wnt-signaling was
shown to regulate the formation and function of neuronal
circuits by controlling neuronal differentiation, axon
outgrowth and guidance, dendrite development, synaptic
function, and neuronal plasticity42,43. Genome-wide
association studies (GWAS) have reported the KCNIP4
gene, known to be associated with ADHD, plays a role in a
negative-feedback loop in the Wnt/β-catenin pathway44.
Several GWAS and candidate gene studies describe the
association of CDH13 (encodes the cadherin-13 protein)
and CTNNA2 (encodes the α2-catenin protein) genes
with ADHD or with associated phenotypes (e.g., hyper-
activity/impulsivity symptoms; verbal working-mem-
ory)45–47 pointing to alterations in the Wnt-associated
genes in ADHD. Furthermore, an enrichment analysis of a
GWAS analyzing the association in a subpopulation of
oppositional deﬁant disorder in ADHD found the β-
catenin to be signiﬁcantly highlighted48. In the often co-
morbid disorder, autism spectrum disorder (ASD), evi-
dence from human genetic data to animal genetic models
also point to the involvement of Wnt-pathway (see review
in ref. 49). In summary, this evidence of dysregulation of
Wnt-pathways in ADHD might also predict the efﬁcacy of
MPH treatment in some patients compared to non-
responders. However, this needs further investigation
using patient speciﬁc cellular models, i.e., induced plur-
ipotent stem cells (iPSC).
In conclusion, this study has shed some light on to the
additional targets of MPH and its inﬂuence on cell pro-
liferation and differentiation. Wnt-signaling alterations
through MPH points to the importance of gaining further
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understanding of its short-term and long-term effects and
duration of treatment. Studies using patients’ speciﬁc
neuronal models will greatly improve the accessibility of
human tissue, which is currently limited due to scarce
postmortem samples from ADHD patients.
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